MARC details
| 000 -LEADER |
|---|
| fixed length control field |
08317namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20251125092805.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
251124s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.99424 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.99424 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.19.03.M.Sc.2025.Sh.V |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Shaimaa Saeed Mohamed Sallam, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Viral infection and genetic mutations in non-small cell lung cancer patients / |
| Statement of responsibility, etc. |
by Shaimaa Saeed Mohamed Sallam ; Supervision Prof. Dr. Mohamed Mahmoud Hafez Ahmed, Prof. Dr. Ahmed Mohamed Ahmed Fahmy, Dr. Amira Salah El-Din Youssef. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
العدوى الفيروسية والطفرات الجينية لدى مرضى سرطان الرئة غير صغيرة الخلايا |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
137 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 119-135. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background: Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, with <br/>non-small cell lung cancer (NSCLC) accounting for approximately 75–80% of cases. Genetic <br/>alterations, particularly somatic mutations in the Epidermal Growth Factor Receptor (EGFR) and <br/>proto-oncogene B-Raf (BRAF) genes, play a critical role in NSCLC tumorigenesis and treatment <br/>responsiveness. Oncogenic viruses, such as Human Papillomavirus (HPV) and Epstein-Barr Virus <br/>(EBV), have also been implicated in various cancers. This study aimed to investigate the <br/>prevalence of EGFR and BRAF mutations in NSCLC Egyptian patients and explore their <br/>association with these oncogenic viruses and its impact on survival rates. <br/>Subjects and Methods: The study included 93 formalin-fixed, paraffin-embedded (FFPE) <br/>NSCLC samples and 10 FFPE tissue as a control samples. EGFR mutations were detected using <br/>the AmoyDx® EGFR 29 Mutations Detection Kit, covering mutations in exons 18, 19, 20, and 21. <br/>Also, BRAF mutations in exon 15 were detected using PCR High Resolution Melting curve assay <br/>(HRM). HPV DNA and its genotypes (16,18,33, and 58) were identified via Qualitative PCR, <br/>while EBV DNA was detected using the Artus EBV TM PCR Kit, targeting the EBNA1 gene. <br/>Results: EGFR mutations were found in 19 of 93 (20.4%) NSCLC patients, predominantly in exon <br/>19 (47.4%), followed by exons 20 (31.6%), 21 (21%), and 18 (10.5%). The most frequently <br/>detected EGFR mutations were: (19 del: 47.4%, T790M: 26.3%, L858R: 21%, G719S: 10.5%, <br/>Insertions: 5.3%) in mutated EGFR patients. BRAF mutations in exon 15 were identified in 11.8% <br/>of the 93 patients studied. Notably, no combined mutations were observed between EGFR and <br/>BRAF.HPV DNA was detected in 31.1% of NSCLC patients, with 26.3% of EGFR-mutated <br/>patients also harboring HPV DNA. Conversely, HPV was absent in all patients with mutated <br/>BRAF. HPV type 16 was the most prevalent, found in 17.2% (5/29) of cases, HPV 18 was found <br/>in 3.4% (1/29) of the positive cases. Neither low-risk HPV types (6/11) nor high-risk types (33 and <br/>58) were detected in any of the samples. EBV DNA was identified in 2.1% of NSCLC patients, <br/>with no presence in those with EGFR or BRAF mutations. No somatic mutations (EGFR, and <br/>BRAF) or oncogenic viruses were found in the control group. No significant association was <br/>observed between the presence of HPV and EGFR mutations (P=0.608); while BRAF mutations <br/>were not detected in positive HPV patients (P=0.017). Regarding the survival, the 5- years overall <br/>survival (OS) was 4.0 %, and the median OS for all patients was 11 months. Furthermore, the <br/>median OS for patients with negative HPV was significantly greater than that for patients with <br/>HPV positive (P=0.003) and Patients without EGFR mutations and HPV infections (HPV- /mutant-<br/>) demonstrated the longest survival time of 14.3 months (P=0.018). <br/>Conclusion: This study highlights the frequency of EGFR and BRAF mutations, the prevalence <br/>of oncogenic viruses, and their association with HPV in NSCLC Egyptian patients, suggesting a <br/>potential interplay in tumorigenesis and OS in these patients. However, larger-scale prospective <br/>studies are needed to confirm these findings and elucidate the prognostic and therapeutic <br/>implications, paving the way for more personalized treatment strategies in NSCLC. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
مقدمة: يعتبر سرطان الرئة هو من أكثر أنواع السرطان المسببة للموت شيوعا في جميع أنحاء العالم حيث يمثل سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC)ما يقرب من 75-80٪ من الحالات.<br/>تضمنت الدراسة 93 عينةمن مرضى سرطان الرئة ذو الخلايا غير الصغيرة مثبتة بالفورمالين ومدمجة في البارافين وأيضا عشرةعينات من الأنسجة السليمة كعينات للمقارنة. النتائج: تم العثور على طفرات مستقبل عامل نمو البشرة EGFRفي 19 مريضا من 93 وذلك بنسبة (20.4%) ،تم تحديدهم في هذه الا كزونات اكزون 19(%42.8) ويليه اكزون 20(28.5%) واكزون 21 (19%) وأخيرا اكزون18(%9.5).وتم تحديد طفرات الجين الورمي البروتيني B-Raf في اكزون 15 في 11.8٪ من 93 مريضا تمت دراستهم. والجدير بالذكر أنه لم يلاحظ أي طفرات مشتركة بين EGFR وBRAF.<br/>تم اكتشاف الحمض النووي لفيروس الورم الحليمي البشري في 31.1٪ من المرضى، مع 26.3٪ من المرضى الذينلديهم طفرات مستقبل عامل نمو البشرة EGFR أيضا لديهم الحمض النووي لفيروس الورم الحليمي البشري. تم تحديد الحمض النووي الخاص بفيروس إبشتاين بار EBVفي 2.1٪ من المرضى. ولم يتم العثور على أى طفرات جسدية أوالفيروسات المكونة للاورام في المجموعة السليمة.كان متوسط معدل البقاء على قيد الحياة لجميع المرضى 11 شهرا. علاوة على ذلك، كان متوسط معدل البقاء على قيد الحياة للمرضى الذين ليس لديهم فيروس الورم الحليمي البشري أكبر بكثير من المرضى الذين لديهم فيروس الورم الحليمي البشري الإيجابي (P=0.003) والمرضى الذين لا يعانون من طفراتمستقبل عامل نمو البشرة EGFR وعدوى فيروس الورم الحليمي البشري أظهروا أطول فترة بقاء على قيد الحياة تبلغ 14.3 شهرا. (P = 0.018)<br/>وقد سلطت هذه الدراسة الضوء على تواتر طفرات EGFR و BRAF، وانتشار الفيروسات المسرطنة، وارتباط هذه الطفرات بفيروس الورم الحليمي البشري لدى مرضى سرطان الرئةذو الخلايا غير الصغيرة، مما يشير إلى تفاعل محتمل في تكوين الأورام ومتوسط بقاء المرضى على الحياة. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
cell lung cancer |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
سرطان الرئة |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Epidermal Growth Factor Receptor (EGFR) |
| -- |
proto-oncogene B-Raf (BRAF) |
| -- |
Human Papillomavirus (HPV) |
| -- |
Epstein-Barr Virus (EBV) |
| -- |
Overall survival (OS) |
| -- |
Non-Small Cell Lung Cancer (NSCLC) |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mohamed Mahmoud Hafez Ahmed |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ahmed Mohamed Ahmed Fahmy |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Amira Salah El-Din Youssef |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Mohamed Mahmoud Hafez Ahmed |
| -- |
Ahmed Mohamed Ahmed Fahmy |
| -- |
Amira Salah El-Din Youssef |
| Universities |
Cairo University |
| Faculties |
National Cancer Institute |
| Department |
Department of Virology and Immunology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |